



Paul L. Berns Joins Jazz Pharmaceuticals' Board of Directors

June 7, 2010

PALO ALTO, Calif., June 7, 2010 /PRNewswire via COMTEX/ --Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced today that Paul L. Berns has been appointed to the company's Board of Directors.

Mr. Berns joined Allos Therapeutics, Inc. as President and Chief Executive Officer and a member of the Board of Directors in March 2006. From June 2002 to July 2005, Mr. Berns was President, Chief Executive Officer and a director of Bone Care International, Inc., a specialty pharmaceutical company that was acquired by Genzyme Corporation in 2005. Prior to that, from 2001 to 2002, Mr. Berns served as Vice President and General Manager of the Immunology, Oncology and Pain Therapeutics business unit of Abbott Laboratories, a pharmaceutical company. From 2000 to 2001, he served as Vice President, Marketing of BASF Pharmaceuticals-Knoll, a pharmaceutical company, and from 1990 to 2000, Mr. Berns held various positions, including senior management roles, at Bristol-Myers Squibb Company, a pharmaceutical company. Mr. Berns is a director of XenoPort, Inc. Mr. Berns received a B.S. in Economics from the University of Wisconsin

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals (Nasdaq: JAZZ) is a specialty pharmaceutical company that identifies, develops and commercializes innovative treatments for important, underserved markets in neurology and psychiatry. For further information see www.jazzpharmaceuticals.com.

SOURCE Jazz Pharmaceuticals, Inc.